Researchers find breast cancer drug in bodybuilding supplement

February 13, 2014

Researchers have found the breast cancer drug tamoxifen in samples of a widely available bodybuilding dietary supplement.

In a letter to The BMJ this week, they explain that, for more than 30 years, bodybuilders have taken tamoxifen to prevent and treat gynaecomastia (breast swelling) caused by use of anabolic steroids.

Usually, is sourced from the illicit market, they say. However, bodybuilding discussion forums have speculated that a dietary supplement called Esto Suppress contains tamoxifen because the label listed one of its chemical names.

The researchers purchased four samples at different times between late 2011 and early 2012 and analysed their contents. Tamoxifen was found in three out of the four samples at different concentrations (3.8 mg, 0.9 mg and 3 mg).

The product label suggested a dosage of two capsules a day, which in the case of sample 1 may have provided 7.6 mg of tamoxifen (10-20 mg is used clinically for treating gynaecomastia).

It is not known whether the Esto Suppress currently being sold still contains tamoxifen, but since the 2000s a growing number of off-the-shelf "food," "herbal," or "dietary" "supplements" - aimed at gym goers and people wanting to lose weight or enhance their sex lives - have contained pharmacologically active substances, explain the authors.

These include , erectogenics (to stimulate erections), stimulants, appetite suppressants, and anxiolytics (to treat anxiety).

Often the substances are not listed on the labelling, and products may be marketed as "natural," exploiting the belief that they are safer and healthier options, they add. In other cases, such as with Esto Suppress, only an obscure reference is made to the substance, such as a chemical name.

They warn that most users "will be unaware that they are taking these substances" and urge healthcare professionals to ask their patients about their use of "supplements" and report suspected adverse reactions.

Explore further: Breast cancer drug fights fungal disease

More information: Paper: www.bmj.com/cgi/doi/10.1136/bmj.g1476

Related Stories

Breast cancer drug fights fungal disease

February 11, 2014
Tamoxifen, a drug currently used to treat breast cancer, also kills a fungus that causes a deadly brain infection in immunocompromised patients. The findings, which could lead to new treatments for a disease that kills more ...

FDA warns of steroids in vitamin B supplement

July 27, 2013
(AP)—The Food and Drug Administration is warning consumers to avoid a vitamin B dietary supplement from Healthy Life Chemistry by Purity First because it contains two potentially dangerous anabolic steroids.

First in-human trial of endoxifen shows promise as breast cancer treatment

December 12, 2013
A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate ...

Tamoxifen trial should prompt breast cancer patients to reconsider treatment options

December 6, 2012
A groundbreaking clinical trial involving the breast cancer drug tamoxifen should prompt certain breast cancer patients to reconsider their treatment options, according to Loyola University Medical Center breast cancer specialist ...

Study confirms long term benefits of tamoxifen

June 3, 2013
(Medical Xpress)—Taking tamoxifen for 10 rather than five years halves the risk of women dying from the most common kind of breast cancer, according to new research being presented at this year's ASCO conference.

Study confirms long term benefits of tamoxifen are relevant to all women who take it for five years

October 1, 2013
Taking tamoxifen for an extra five years benefits women with breast cancer that has not spread to the lymph glands (node negative disease), as well as women where lymph node spread was found at operation, updated research ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.